Home

Applications

APPLICATIONS OVERVIEW
DRUG DISCOVERY
ADME-Tox
Biochemical Assays
Cell-based Assays
HTS and Secondary Screening
Microsampling
Protein Crystallography
RNAi
Sample Management
CANCER RESEARCH
Personalized Medicine
Functional Screening / DSRT
RNAi
Sequencing
Single-cell Genomics
GENOMIC RESEARCH
Gene Expression
Genotyping
Microbiome
qPCR
Sequencing
Single-cell Genomics
Synthetic Biology

Products

LIQUID HANDLING
LIQUID HANDLERS OVERVIEW
Echo® 525 Liquid Handler
Echo® 555 Liquid Handler
Echo® 550 Liquid Handler
Echo® 520 Liquid Handler
AUTOMATION
AUTOMATION OVERVIEW
Access™ Laboratory Workstation
Tempo™ Automation Control Software
SOFTWARE APPLICATIONS
SOFTWARE OVERVIEW
Echo® Array Maker
Echo® Cherry Pick
Echo® Combination Screen
Echo® Compliance Manager
Echo® Dose-Response
Echo® Plate Audit
Echo® Plate Reformat
CONSUMABLES
CONSUMABLES OVERVIEW
Echo® Qualified Microplates
Labcyte® Assay Microplates
MicroClime® Environmental Lid
Echo® Qualified Reservoir

Technology

Echo® Acoustic Liquid Handling
Dynamic Fluid Analysis™
Acoustic Mass Spectrometry
Direct Dilution

News / Events

Labcyte BLOG
Upcoming Events
Press Releases
Labcyte in the News
Labcyte Community

Resources

JALA Special Issue
Publications
Articles and Other Media
Application Notes
Posters
Webinars
Videos
Customer Profiles
Core Labs

Support

Brochures
Web Documentation*
User Guides*
Quick Start Guides*
Specification Sheets
Site Prep Guides
Service and Maintenance
Request Information

Company

About Us
Echo® Acoustic Technology
Leadership Team
Meet Labcyte
Careers
Contact and Location
Privacy Policy

Labcyte Acoustic Platform Essential to Identification of Novel Cancer Drug Candidates

AstraZeneca Issued US Patent 7,718,653

September 24, 2010

Sunnyvale, CA

Sunnyvale, CA — December 14, 2010 — When the revolutionary Echo® acoustic liquid handler is used in the process of discovering potential therapeutics, important drug candidates are identified that are missed using traditional liquid handlers. In a recently issued patent, the global pharmaceutical company AstraZeneca describes the discovery of a novel set of potential cancer therapeutics that was found only when the Echo system was used. Other major pharmaceutical companies have also reported that the Echo liquid handler was a critical platform in discovering drug candidates.

The Echo system uses acoustic energy to transfer liquids during the drug discovery testing process, avoiding problems associated with transferring potential drug candidates with pipette tips. Drug candidates can be lost when pipette tips become clogged or if the candidate sticks to the tip. Test results can also be compromised by dirty tips or by chemicals leaching from tips. These errors are compounded when doing dose-response experiments. The Echo system reduces false negative and false positive results, leading to better identification of potential therapies.

“Echo systems have been described as revolutionary by our customers, who include all ten of the top 10 pharmaceutical companies. Our products play a key part of the drug discovery process for biotech companies, contract research organizations and academic institutions,” said Labcyte Chief Executive Officer and President, Mark Fischer-Colbrie. “Echo systems increase productivity, significantly reduce costs and most importantly, generate better results—results that may lead to new therapies. This path-breaking approach of using sound to move liquids has also been adopted by customers for qPCR, siRNA testing, tissue-imaging mass spectroscopy, cell transfers and protein crystallography.”


About Labcyte Inc.

Labcyte, a global biotechnology tools company, is revolutionizing liquid handling. Echo liquid handling platforms use sound for the precise transfer of liquids. The environmentally-friendly Echo systems generate better results with significantly lower costs when compared to traditional liquid handling systems that have high running costs, are prone to transfer errors, have risk of sample contamination and waste large amounts of plastic lab consumables. Labcyte equipment is used by all 10 of the top 10 pharmaceutical companies, as well as by small to mid-size pharmaceutical companies, biotechnology firms, contract research organizations and academic institutions. Our customers work across a wide spectrum of biology including drug discovery; genomics; proteomics; diagnostics; imaging mass spectrometry and the transfer of live cells. Labcyte, headquartered in Sunnyvale, California, has global sales and support. Labcyte has 41 U.S. and 12 international patents with additional applications pending. For more information, visit www.labcyte.com.





MAIN CONTACT
LABCYTE INC.
170 Rose Orchard Way
San Jose, California 95134
USA
Tel:
+1 408 747-2000
Toll-free:
+1 877 742-6548
Sales:
+1 877 742-6548, option 1
Fax:
+1 408 747-2010
Contact:
REQUEST INFO

PRESS CONTACT
Nicole Litchfield
Bioscribe, Inc.
Tel:
+1 415 793-6468
Email:
nicole@bioscribe.com
TOP